Albumin has been identified as a powerful natural defense against mucormycosis, with low levels signaling heightened risk and a potential opportunity for new preventive therapies. An international ...
EPO grants Sonnet EU Patent No. EP3583125 B1 for Fully Human Albumin Binding (FHAB®) domain fusion proteins, expanding global IP protection. Sonnet BioTherapeutics Holdings, Inc. announced that the ...
Study identifies blood protein albumin as key defense against deadly fungal infection “mucormycosis”
A new international study published in Nature has identified albumin, the most abundant protein in human blood, as a powerful ...
Albumin triggers fungal virulence: Candida albicans forms denser biofilms in the presence of human albumin (right) compared to its absence (left), revealing a hidden pathogenicity pathway. Candida ...
Identification of disease biomarkers has significantly increased interest in studying the plasma proteome. The plasma proteome has a large, dynamic range of individual protein concentrations, which ...
Albumin is a major prognostic factor for patients with advanced liver disease, dependent on its concentration and biological activity. This study aimed to improve the method of active albumin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results